Compare ALGN & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGN | ALKS |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.7B |
| IPO Year | 2000 | 2012 |
| Metric | ALGN | ALKS |
|---|---|---|
| Price | $155.44 | $44.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | ★ $193.79 | $56.21 |
| AVG Volume (30 Days) | 857.9K | ★ 2.0M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.53 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | $387,126,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $2.95 | $23.54 |
| Revenue Next Year | $3.76 | $6.53 |
| P/E Ratio | $49.04 | ★ N/A |
| Revenue Growth | ★ 23.95 | N/A |
| 52 Week Low | $130.23 | $27.00 |
| 52 Week High | $200.44 | $55.67 |
| Indicator | ALGN | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 58.24 |
| Support Level | $153.21 | $39.41 |
| Resistance Level | $162.92 | $47.40 |
| Average True Range (ATR) | 3.77 | 1.46 |
| MACD | 1.91 | 0.68 |
| Stochastic Oscillator | 99.83 | 87.62 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.